Hetero Enters Into a Licensing Agreement With Gilead Sciences, Inc. for the Manufacturing and Distribution of "Remdesivir" in 127 Countries, Including India, for COVID-19
Under this licensing deal, Hetero will be supplying Remdesivir in 127 countries, including India, subject to regulatory approvals in respective countries.
- Under this licensing deal, Hetero will be supplying Remdesivir in 127 countries, including India, subject to regulatory approvals in respective countries.
- This agreement also illustrates the significance of global collaboration and the need for coming together to fight the health crises impacting humanity.
- U.S. Food and Drug Administration(FDA) has granted emergency use authorization (EUA) for the investigational antiviral Remdesivir to treat COVID-19.
- Hetero has 36 state-of-the-art manufacturing facilities, 300 plus products in its portfolio and has a strong global presence in over 126 countries.